fbpx

Pfizer Halts Sales of Chantix Due To Possible Carcinogen Contamination

Last month, Pfizer announced a pause in the distribution of smoking-cessation drug Chantix (varenicline) after identifying levels of nitrosamines, a potential carcinogen. The levels in drugs aren’t supposed to exceed an excess cancer risk of 1 in 100,000. The manufacturer is recalling multiple lots of the drug for the same reason.

In 2020, the Food and Drug Administration (FDA) discovered high amounts of NDMA (N-nitrosadimethylamine) in numerous drugs, including the diabetes drug metformin. In 2019, heartburn medication Zantac was also recalled due to NDMA contamination.

The History of Chantix

Chantix, which is used for 12 to 24 weeks, was initially approved by the FDA in May 2006 to help adults 18 and over quit smoking. Pfizer indicated that they were stopping distribution “out of an abundance of caution” and would continue investigations. They haven’t revealed which nitrosamines were discovered in the pills or how they got there. 

Prior to the sales halt, the drug was already facing issues. Sales recently dropped 17 percent — from $1.1 billion in 2019 to $919 million in 2020 — due to the COVID-19 pandemic and the loss of patent protection in the United States in November.

As company spokesperson Steven Danehy told Reuters, Pfizer believe “the benefits of Chantix outweigh the very low potential risks, if any, posed by nitrosamine exposure from varenicline on top of other common sources over a lifetime.” It’s important to note that the potential carcinogen is also found in water and grilled meat. 

For more information about the halted distribution of Chantix, contact us today.

Tracy Everhart is the Editor for Drug Law Journal. A highly-trained and certified medical professional, Tracy is also an accomplished medical writer. After spending years on the front lines of the medical profession, Tracy now devotes her expertise and skills to researching and reporting on new drugs and devices that enter the market, as well as their side-effects and the real-life stories involved. Prior to joining Drug Law Journal, Tracy wrote for benchmark online healthcare resources focused on families and, in particular, women’s health issues. Tracy holds post-graduate degrees from both the American College of Healthcare Sciences and the Yale School of Nursing. She is also a graduate of both Hampshire College, where she studied microbiology and the University of South Carolina school of nursing.

Drug Law Journal Legal Sponsorship

Drug Law Journal's publishing and research are sponsored by the DDP Injury Law Group in Washington, D.C. Their legal team is focused on protecting the rights of injury victims.
Furthermore, they understand and appreciate the importance of a trusted attorney-client relationship.
The DDP Injury Law Group uses their years of experience with litigation to ensure their clients can fight for the compensation they deserve.

Always seek the advice of a medical professional when making personal health choices.

The Offices of DrugLawJournal.com are located at:

1800 North Orange Avenue, Suite C
Orlando, Florida 32804

DrugLawJournal.com is sponsored by the DDP Injury Law Group, and therefore may be considered attorney advertising. The information contained on DrugLawJournal.com is provided for informational purposes only, and should not be construed as legal or medical advice on any subject matter. No viewers of this site should discontinue taking a prescribed medication on the basis of any information on this site and should always first consult with a doctor concerning any medication. Viewers should understand that if they refrain from taking prescribed medication without appropriate medical advice they can suffer injury or death.

No viewers of content from this site, clients or otherwise, should act or refrain from acting on the basis of any content included in the site without seeking the appropriate legal or other professional advice on the particular facts and circumstances at issue from an attorney licensed in the viewer’s state. Viewing information from DrugLawJournal.com does not create an attorney-client relationship between you and DDP Injury Law Group or DrugLawJournal.com nor is it intended to do so.The content of DrugLawJournal.com may not reflect current legal developments, verdicts or settlements. Prior results do not predict a similar outcome. For more information, please visit our web site’s disclaimer.

©2024 DrugLawJournal.com | Privacy Policy | Terms & Conditions

Stay Informed

Sign up to receive peroidic updates from our expert team of researchers, highlighting defective drugs, devices, and legal issues related to your health.

Email Catcher
Free Drug and Medical Device Case Review

Free Drug and Medical Device Case Review

Share your story with us and we will reach out to you about your case.

First
Last
Described what happened to you, we will review and reach out to you about your situation.

It is important for those who have suffered injury from dangerous drugs and medical devices to know that they have may have options.

Consumers have the ability to seek legal remedies for their injuries resulting from the negligence of drug and device manufacturers. The first step toward justice and recovery is sharing your story with effective legal counsel. An attorney will help you to better understand the issues and discuss the possibility of compensation for your suffering.

Once you complete the information request above, Drug Law Journal will send the information to a specialist at our legal sponsor’s firm, the DDP Injury Law Group, in Washington, D.C. That specialist will follow-up with you directly to gather further specific information about your case and make an evaluation. If the firm is able to move forward on your case, they will also discuss next steps. Remember – the entire consult and evaluation is free to you. You only need to take the first step to fill out the contact form or call: (800) 597-1870 for immediate assistance.